| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q3'26 | October 20, 2026 | 8/12 | 2 medium, 2 low flags | 1 | 0 | Call sheet → |
| Q2'26 | July 16, 2026 | 4/12 | 2 high, 3 medium, 1 low flags | 3 | 0 | Call sheet → |
| Q1'26 | 2026-04-21 | 11/12 | 2 medium, 4 low flags | 5 | 0 | Call sheet → |
| Q4'25 | January 22, 2026 | 10/12 | 6 low flags | 7 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q3'26 | Pending | We expect availability to extend to Japan in Q3 Q3 has now been reported, but the current transcript does not explicitly state whether SP stapler Japan availability was achieved; actual not stated on the call. |
| Q3'26 | Pending | Full year 2026 da Vinci procedure growth within 13.5% to 15.5%, with an expectation to be closer to the midpoint Full year period not yet ended; narrowed this quarter to 14%-15%, still expecting closer to midpoint, a revision not a resolution. |
| Q3'26 | Delivered | We are still finalizing pricing for this initiative, and will provide additional quantification on our next earnings call Quantified at 3-5% INA revenue-per-procedure impact this quarter, as promised. |
| Q2'26 | Exceeded | Gross margin 67.5%-68.5% for 2026 Raised to 68%-69% but includes one-time tariff benefit |
| Q2'26 | Pending | Continue to advance ROSE and EBUS programs Mentioned 'making strong progress' but no concrete milestones achieved |
| Q2'26 | Pending | Full year 2026 da Vinci procedure growth 13.5%-15.5% Maintained range but now guiding to midpoint, suggesting lower confidence |
| Q2'26 | Delivered | Japan reimbursement changes effective June 1 Confirmed went into effect June 1 with 7 new procedures covered |
| Q2'26 | Pending | SP stapler to move into measured launch in Korea and Europe in Q2 Mentioned planning to move to measured launch but no confirmation it happened |
| Q2'26 | Delivered | We expect to increase da Vinci 5 Force Feedback instrument availability in Q2 FDA clearance received in March, broader availability confirmed in Q2 |
| Q1'26 | Delivered | Japan reimbursement update by Q1 call 7 new procedures reimbursed starting June 2026 |
| Q1'26 | Exceeded | XiR refurbished system launch 34 systems placed vs 2 prior year, ahead of expectations |
| Q1'26 | Delivered | Cardiac clearance on da Vinci 5 FDA cleared cardiac procedures in Q1 |
| Q1'26 | Delivered | SP stapler broad launch Moved to broad launch in Q1, used in 40% of expected cases |
| Q1'26 | Delivered | da Vinci 5 international expansion in H2 2025 40 OUS systems placed in Q1, Europe and Japan launched |
| Q1'26 | Pending | Force Feedback broader availability following manufacturing scale Still constrained through Q2 with gradual improvement - manufacturing ramp slower than implied |
| Q4'25 | Delivered | Q3: Going direct in Italy, Spain, Portugal 'first half of 2026' Now closing by end of Q1 2026, ahead of schedule |
| Q4'25 | Delivered | Q3: Updated 2025 da Vinci procedure growth to 17-17.5% Actual growth was ~18%, at high end of raised guidance |
| Q4'25 | Delivered | Q3: 'Continued progress in building industrial scale' Scaled dV5 manufacturing throughout the year, placed 870 systems |
| Q4'25 | Delivered | Q3: 'SP stapler initial launch' progress Moved from initial to broad launch this quarter with 'very positive' feedback |
| Q4'25 | Delivered | Q3: 'Regulatory submissions for nipple-sparing mastectomy' Received 510(k) clearance for NSM and other general surgery procedures |
| Q4'25 | Exceeded | Q3: 'First nine da Vinci 5 systems in Japan and Europe' Placed 43 dV5 systems OUS in Q4, mostly in Europe |
| Q4'25 | Delivered | Q3: 'Working closely with customers to support analyses of Force Feedback impact' Published Force Feedback thoracic surgery study showing 20% reduction in peak force application |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.